vs
Side-by-side financial comparison of Kenvue (KVUE) and Roper Technologies (ROP). Click either name above to swap in a different company.
Kenvue is the larger business by last-quarter revenue ($3.8B vs $2.1B, roughly 1.8× Roper Technologies). Roper Technologies runs the higher net margin — 15.8% vs 8.7%, a 7.1% gap on every dollar of revenue. On growth, Roper Technologies posted the faster year-over-year revenue change (11.3% vs 3.2%). Kenvue produced more free cash flow last quarter ($744.0M vs $507.0M). Over the past eight quarters, Roper Technologies's revenue compounded faster (10.5% CAGR vs -1.5%).
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
KVUE vs ROP — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.8B | $2.1B |
| Net Profit | $330.0M | $331.0M |
| Gross Margin | 56.5% | 69.4% |
| Operating Margin | 14.2% | 27.2% |
| Net Margin | 8.7% | 15.8% |
| Revenue YoY | 3.2% | 11.3% |
| Net Profit YoY | 12.6% | 53.7% |
| EPS (diluted) | $0.16 | $4.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.1B | ||
| Q4 25 | $3.8B | $2.1B | ||
| Q3 25 | $3.8B | $2.0B | ||
| Q2 25 | $3.8B | $1.9B | ||
| Q1 25 | $3.7B | $1.9B | ||
| Q4 24 | $3.7B | $1.9B | ||
| Q3 24 | $3.9B | $1.8B | ||
| Q2 24 | $4.0B | $1.7B |
| Q1 26 | — | $331.0M | ||
| Q4 25 | $330.0M | $428.4M | ||
| Q3 25 | $398.0M | $398.5M | ||
| Q2 25 | $420.0M | $378.3M | ||
| Q1 25 | $322.0M | $331.1M | ||
| Q4 24 | $293.0M | $462.3M | ||
| Q3 24 | $383.0M | $367.9M | ||
| Q2 24 | $58.0M | $337.1M |
| Q1 26 | — | 69.4% | ||
| Q4 25 | 56.5% | 69.5% | ||
| Q3 25 | 59.1% | 69.5% | ||
| Q2 25 | 58.9% | 69.2% | ||
| Q1 25 | 58.0% | 68.7% | ||
| Q4 24 | 56.5% | 68.3% | ||
| Q3 24 | 58.5% | 69.2% | ||
| Q2 24 | 59.1% | 69.5% |
| Q1 26 | — | 27.2% | ||
| Q4 25 | 14.2% | 28.6% | ||
| Q3 25 | 16.7% | 28.4% | ||
| Q2 25 | 18.0% | 28.2% | ||
| Q1 25 | 14.9% | 27.9% | ||
| Q4 24 | 13.2% | 28.0% | ||
| Q3 24 | 16.8% | 28.1% | ||
| Q2 24 | 3.9% | 28.8% |
| Q1 26 | — | 15.8% | ||
| Q4 25 | 8.7% | 20.8% | ||
| Q3 25 | 10.6% | 19.8% | ||
| Q2 25 | 10.9% | 19.5% | ||
| Q1 25 | 8.6% | 17.6% | ||
| Q4 24 | 8.0% | 24.6% | ||
| Q3 24 | 9.8% | 20.8% | ||
| Q2 24 | 1.5% | 19.6% |
| Q1 26 | — | $4.87 | ||
| Q4 25 | $0.16 | $3.97 | ||
| Q3 25 | $0.21 | $3.68 | ||
| Q2 25 | $0.22 | $3.49 | ||
| Q1 25 | $0.17 | $3.06 | ||
| Q4 24 | $0.16 | $4.29 | ||
| Q3 24 | $0.20 | $3.40 | ||
| Q2 24 | $0.03 | $3.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $382.9M |
| Total DebtLower is stronger | — | $9.7B |
| Stockholders' EquityBook value | $10.8B | $18.8B |
| Total Assets | $27.1B | $34.6B |
| Debt / EquityLower = less leverage | — | 0.52× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $382.9M | ||
| Q4 25 | $1.1B | $297.4M | ||
| Q3 25 | $1.1B | $320.0M | ||
| Q2 25 | $1.1B | $242.4M | ||
| Q1 25 | $1.1B | $372.8M | ||
| Q4 24 | $1.1B | $188.2M | ||
| Q3 24 | $1.1B | $269.6M | ||
| Q2 24 | $1.0B | $251.5M |
| Q1 26 | — | $9.7B | ||
| Q4 25 | — | $9.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $18.8B | ||
| Q4 25 | $10.8B | $19.9B | ||
| Q3 25 | $10.6B | $20.0B | ||
| Q2 25 | $10.7B | $19.6B | ||
| Q1 25 | $10.1B | $19.2B | ||
| Q4 24 | $9.7B | $18.9B | ||
| Q3 24 | $10.6B | $18.5B | ||
| Q2 24 | $10.2B | $18.1B |
| Q1 26 | — | $34.6B | ||
| Q4 25 | $27.1B | $34.6B | ||
| Q3 25 | $27.2B | $34.6B | ||
| Q2 25 | $27.1B | $33.2B | ||
| Q1 25 | $26.3B | $31.4B | ||
| Q4 24 | $25.6B | $31.3B | ||
| Q3 24 | $26.9B | $31.6B | ||
| Q2 24 | $26.4B | $29.8B |
| Q1 26 | — | 0.52× | ||
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $854.0M | — |
| Free Cash FlowOCF − Capex | $744.0M | $507.0M |
| FCF MarginFCF / Revenue | 19.7% | 24.2% |
| Capex IntensityCapex / Revenue | 2.9% | 0.5% |
| Cash ConversionOCF / Net Profit | 2.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.7B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $854.0M | $738.0M | ||
| Q3 25 | $294.0M | $869.5M | ||
| Q2 25 | $621.0M | $404.1M | ||
| Q1 25 | $428.0M | $528.7M | ||
| Q4 24 | $793.0M | $722.2M | ||
| Q3 24 | $249.0M | $755.4M | ||
| Q2 24 | $440.0M | $384.1M |
| Q1 26 | — | $507.0M | ||
| Q4 25 | $744.0M | — | ||
| Q3 25 | $196.0M | — | ||
| Q2 25 | $533.0M | — | ||
| Q1 25 | $249.0M | — | ||
| Q4 24 | $661.0M | — | ||
| Q3 24 | $190.0M | — | ||
| Q2 24 | $350.0M | — |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 19.7% | — | ||
| Q3 25 | 5.2% | — | ||
| Q2 25 | 13.9% | — | ||
| Q1 25 | 6.7% | — | ||
| Q4 24 | 18.1% | — | ||
| Q3 24 | 4.9% | — | ||
| Q2 24 | 8.8% | — |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 2.9% | — | ||
| Q3 25 | 2.6% | — | ||
| Q2 25 | 2.3% | — | ||
| Q1 25 | 4.8% | — | ||
| Q4 24 | 3.6% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 2.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.59× | 1.72× | ||
| Q3 25 | 0.74× | 2.18× | ||
| Q2 25 | 1.48× | 1.07× | ||
| Q1 25 | 1.33× | 1.60× | ||
| Q4 24 | 2.71× | 1.56× | ||
| Q3 24 | 0.65× | 2.05× | ||
| Q2 24 | 7.59× | 1.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KVUE
| Self Care | $1.6B | 42% |
| Essential Health | $1.1B | 30% |
| Skin Health And Beauty | $1.0B | 28% |
ROP
Segment breakdown not available.
